GeneDx Faces Investor Lawsuits Following Massive Stock Collapse

GeneDx Faces Investor Lawsuits Following Massive Stock Collapse

2026-08-03 companies

New York, Sunday, 2 August 2026.
GeneDx Holdings faces shareholder lawsuits after a $31.2 million write-down on Fabric Genomics caused its stock price to plunge over 49% in a single day.

Securities Fraud Litigation and Lead Plaintiff Deadline

GeneDx Holdings Corp. (NASDAQ: WGS) is currently facing a class action securities lawsuit filed by multiple law firms alleging securities fraud and investor harm [1][2]. The legal action urges affected shareholders to take notice as the deadline to seek lead plaintiff status expires on August 3, 2026, marking a critical juncture for institutional and retail investors seeking recovery of potential financial losses [1][3]. Today, Sunday, 2 August 2026, investors have one day remaining to request that the Court appoint them as lead plaintiff in the federal securities class action [2][5]. The lawsuit covers investors who purchased or acquired GeneDx securities between April 16, 2025, and May 4, 2026 [2][4]. Bronstein, Gewirtz & Grossman, LLC announced the filing on August 2, 2026, and is representing investors on a contingency fee basis [1].

Market Reaction to Financial Disclosures

The legal proceedings stem from disclosures made on May 4, 2026, when GeneDx shares closed at $67.93 before after-hours announcements triggered a significant decline [2]. Following the May 4, 2026 disclosures, GeneDx revealed an average reimbursement rate of $3,300, which was $200 below expectations, and reported Q1 misses for exome and genome lines [2][6]. The company also reported a $31.3 million goodwill impairment charge related to the $36.5 million Fabric Genomics acquisition [2]. Consequently, the share price subsequently fell over 49%, dropping $33.42 per share to close at $34.51 in a single trading session [5][6]. This decline represents a calculation of -49.198 based on the reported price points [6]. Additionally, the company cut 2026 revenue guidance from $540–555 million to $475–490 million [2][3].

Allegations of Misleading Statements

The lawsuit alleges defendants misled investors regarding the importance of Fabric Genomics, company margins, and the durability of reimbursement rates, rendering previous positive statements materially false or lacking a reasonable basis [1]. Specifically, the complaint alleges that the Company and its executives violated federal securities laws by failing to disclose that the Company’s gross margins would decline [2][6]. On May 4, 2026, GeneDx reported 2026 Q1 results, disclosing an adjusted gross margin decline from 74% to 69% [3][5]. The allegations further include failure to disclose significant viability issues regarding Fabric Genomics, a company acquired by GeneDx on April 16, 2025 [3][6]. Hagens Berman partner Reed Kathrein stated the complaint alleges investors were misled by management’s positive statements regarding the Fabric Genomics integration and its supposed AI-driven efficiencies [6].

Multiple firms are involved in the litigation, including Robbins Geller Rudman & Dowd LLP, which filed case Basma v. GeneDx Holdings Corp., No. 26-cv-00880 (D. Conn.) [3][5]. Investors who purchased common stock during the Class Period have until August 3, 2026, to seek appointment as lead plaintiff [3][4]. Appointment as lead plaintiff is not required to partake in any potential future recovery [4][5]. Robbins Geller Rudman & Dowd LLP ranked #1 on the ISS Securities Class Action Services Top 50 Report in 2025 and reports recovering $8.4 billion for investors between 2021 and 2025 [3]. Interested parties are invited to contact the respective law firms to discuss legal representation regarding the potential case [2][8]. Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC, stated their practice centers on restoring investor capital and ensuring corporate accountability [1][7].

Sources


Securities Litigation GeneDx